Low levels of IgG autoantibodies against the apolipoprotein B antigen p210 increases the risk of cardiovascular death after carotid endarterectomy

Atherosclerosis

Volumn 239, Issue 2, 2015, Pages 289-294

  Asciutto, Giuseppe ^a   Dias, Nuno V ^a   Edsfeldt, Andreas ^a,b   Alm, Ragnar ^b   Fredrikson, Gunilla N ^b   Gonçalves, Isabel ^a,b   Nilsson, Jan ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Apolipoprotein B; Autoantibodies; Cardiovascular events; Carotid stenosis

Indexed keywords

ANTIGEN; APOLIPOPROTEIN B ANTIGEN P210; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G ANTIBODY; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100; AUTOANTIBODY; EPITOPE; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN;

AGE; AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CAROTID ENDARTERECTOMY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; ENZYME LINKED IMMUNOSORBENT ASSAY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; OBESITY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; SEX; SMOKING HABIT; ATHEROSCLEROSIS; BLOOD; CARDIOVASCULAR DISEASE; CAROTID ARTERY; CAROTID ARTERY OBSTRUCTION; CHEMISTRY; DISEASE FREE SURVIVAL; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK; STENOSIS, OCCLUSION AND OBSTRUCTION; TREATMENT OUTCOME;

AGED; ANTIGENS; APOLIPOPROTEIN B-100; ATHEROSCLEROSIS; AUTOANTIBODIES; CARDIOVASCULAR DISEASES; CAROTID ARTERIES; CAROTID STENOSIS; CONSTRICTION, PATHOLOGIC; DISEASE-FREE SURVIVAL; ENDARTERECTOMY, CAROTID; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULIN G; KAPLAN-MEIER ESTIMATE; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK; TREATMENT OUTCOME;

EID: 84922572165     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.01.023     Document Type: Article

References (35)

1. North American symptomatic carotid endarterectomy Trial. Methods, patient characteristics, and progress. Stroke J. Cereb. Circ. 1991, 22:711-720.
2. Endarterectomy for asymptomatic carotid artery stenosis. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. JAMA J. Am. Med. Assoc. 1995, 273:1421-1428.
3. Nilsson J., Bjorkbacka H., Fredrikson G.N. Apolipoprotein B100 autoimmunity and atherosclerosis - disease mechanisms and therapeutic potential. Curr. Opin. Lipidol. 2012, 23:422-428.
4. Hazen S.L. Oxidized phospholipids as endogenous pattern recognition ligands in innate immunity. J.Biol. Chem. 2008, 283:15527-15531.
5. Witztum J.L., Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J.Clin. Investig. 1991, 88:1785-1792.
6. Keidar S., Kaplan M., Shapira C., et al. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis 1994, 107:71-84.
7. Torzewski M., Rist C., Mortensen R.F., et al. C-reactive protein in the arterial intima: role of C-reactive protein receptor-dependent monocyte recruitment in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2094-2099.
8. Santos A.O., Fonseca F.A., Fischer S.M., et al. High circulating autoantibodies against human oxidized low-density lipoprotein are related to stable and lower titers to unstable clinical situation. Clin. Chim. Acta Int. J. Clin. Chem. 2009, 406:113-118.
9. Hansson G.K. Inflammation and immune response in atherosclerosis. Curr. Atheroscler. Rep. 1999, 1:150-155.
10. Palinski W., Witztum J.L. Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis. J.Intern. Med. 2000, 247:371-380.
11. Libby P. Changing concepts of atherogenesis. J.Intern. Med. 2000, 247:349-358.
12. Puurunen M., Manttari M., Manninen V., et al. Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch. Intern. Med. 1994, 154:2605-2609.
13. Salonen J.T., Yla-Herttuala S., Yamamoto R., et al. Autoantibody against oxidised LDL and progression of carotid atherosclerosis. Lancet 1992, 339:883-887.
14. Bergmark C., Wu R., de Faire U., et al. Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler. Thromb. Vasc. Biol. 1995, 15:441-445.
15. Faviou E., Vourli G., Nounopoulos C., et al. Circulating oxidized low density lipoprotein, autoantibodies against them and homocysteine serum levels in diagnosis and estimation of severity of coronary artery disease. Free Radic. Res. 2005, 39:419-429.
16. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N.Engl. J. Med. 2005, 352:1685-1695.
17. Hansson G.K., Hermansson A. The immune system in atherosclerosis. Nat. Immunol. 2011, 12:204-212.
18. Asciutto G., Edsfeldt A., Dias N.V., et al. Treatment with beta-blockers is associated with lower levels of Lp-PLA2 and suPAR in carotid plaques. Cardiovasc. Pathol. Off. J. Soc. Cardiovasc. Pathol. 2013, 22:438-443.
19. Fredrikson G.N., Hedblad B., Berglund G., et al. Identification of immune responses against aldehyde-modified peptide sequences in apoB associated with cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 2003, 23:872-878.
20. McLeod O., Silveira A., Fredrikson G.N., et al. Plasma autoantibodies against apolipoprotein B-100 peptide 210 in subclinical atherosclerosis. Atherosclerosis 2014, 232:242-248.
21. Lichtman A.H., Binder C.J., Tsimikas S., et al. Adaptive immunity in atherogenesis: new insights and therapeutic approaches. J.Clin. Investig. 2013, 123:27-36.
22. Nilsson J., Hansson G.K. Autoimmunity in atherosclerosis: a protective response losing control?. J.Intern. Med. 2008, 263:464-478.
23. Daugherty A., Pure E., Delfel-Butteiger D., et al. The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice. J.Clin. Investig. 1997, 100:1575-1580.
24. Mallat Z., Ait-Oufella H., Tedgui A. Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc. Med. 2007, 17:113-118.
25. Binder C.J., Shaw P.X., Chang M.K., et al. The role of natural antibodies in atherogenesis. J.Lipid Res. 2005, 46:1353-1363.
26. Binder C.J., Horkko S., Dewan A., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat. Med. 2003, 9:736-743.
27. Schiopu A., Bengtsson J., Soderberg I., et al. Recombinant human antibodies against aldehyde-modified apolipoprotein B-100 peptide sequences inhibit atherosclerosis. Circulation 2004, 110:2047-2052.
28. Schiopu A., Frendeus B., Jansson B., et al. Recombinant antibodies to an oxidized low-density lipoprotein epitope induce rapid regression of atherosclerosis in apobec-1(-/-)/low-density lipoprotein receptor(-/-) mice. J.Am. Coll. Cardiol. 2007, 50:2313-2318.
29. Li S., Kievit P., Robertson A.K., et al. Targeting oxidized LDL improves insulin sensitivity and immune cell function in obese Rhesus macaques. Mol. Metab. 2013, 2:256-269.
30. Nilsson J., Kovanen P.T. Will autoantibodies help to determine severity and progression of atherosclerosis?. Curr. Opin. Lipidol. 2004, 15:499-503.
31. Fredrikson G.N., Anand D.V., Hopkins D., et al. Associations between autoantibodies against apolipoprotein B-100 peptides and vascular complications in patients with type 2 diabetes. Diabetologia 2009, 52:1426-1433.
32. Engelbertsen D., Anand D.V., Fredrikson G.N., et al. High levels of IgM against methylglyoxal-modified apolipoprotein B100 are associated with less coronary artery calcification in patients with type 2 diabetes. J.Intern. Med. 2012, 271:82-89.
33. Fredrikson G.N., Schiopu A., Berglund G., et al. Autoantibody against the amino acid sequence 661-680 in apo B-100 is associated with decreased carotid stenosis and cardiovascular events. Atherosclerosis 2007, 194:e188-192.
34. Frostegard J. Low level natural antibodies against phosphorylcholine: a novel risk marker and potential mechanism in atherosclerosis and cardiovascular disease. Clin. Immunol. 2010, 134:47-54.
35. Fredrikson G.N., Hedblad B., Berglund G., et al. Association between IgM against an aldehyde-modified peptide in apolipoprotein B-100 and progression of carotid disease. Stroke J. Cereb. Circulation 2007, 38:1495-1500.